European equities traded in the US as American depositary receipts were tracking lower late Wednesday morning, declining 0.93% to 1,450.69 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biotech firm Evaxion (EVAX) and furniture maker Natuzzi (NTZ), which advanced 14% and 11% respectively. They were followed by biopharmaceutical company Genfit (GNFT) and internet browser company Opera (OPRA), which rose 1.9% and 1.7% respectively.

The decliners from continental Europe were led by Spanish lender Banco Bilbao Vizcaya Argentaria (BBVA) and pharmaceutical company Novo Nordisk (NVO), which fell 2.1% and 1.8% respectively. They were followed by Dutch financial services company ING (ING) and petroleum refiner Equinor (EQNR), which were down 1.5% and 1.3% respectively.

From the UK and Ireland, the gainers were led by biotech firm Autolus Therapeutics (AUTL) and biopharmaceutical company Bicycle Therapeutics (BCYC), which climbed 4.5% and 4.3% respectively. They were followed by biopharmaceutical companies Amarin (AMRN) and Adaptimmune Therapeutics (ADAP), which advanced 1.9% and 1.4% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and NuCana (NCNA), which dropped 6.1% and 2.9% respectively. They were followed by biotech firm Trinity Biotech (TRIB) and utilities company National Grid (NGG), which lost 2.7% and 2.4% respectively.